PIRCHE Announces Collaboration with Veloxis Pharmaceuticals to Provide Epitope Matching Analysis for the Development of Pegrizeprument

BERLIN, GERMANY – January 14, 2026 – PIRCHE, a leader in advanced molecular transplant diagnostics, today announced its collaboration with Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation. Through the collaboration, PIRCHE will provide epitope matching analysis to support Veloxis' development efforts for its investigational product Pegrizeprument (also known as VEL-101)

Pegrizeprument is a novel investigational maintenance immunosuppressive agent being developed for the prevention of acute rejection in solid organ transplant recipients. The collaboration aims to leverage PIRCHE’s proprietary epitope-matching technology to provide deeper immunological insights during the developmental phase of the Pegrizeprument program.

Leadership Perspectives

Thomas Klein, CEO of PIRCHE, commented on the synergy between the two organizations:
"Our collaboration with Veloxis is expected to be a significant step in understanding individual responses to transplant medicines. By integratingPIRCHE’s advanced immunological risk assessment with the development of Pegrizeprument, we aim to better understand patient responses and ultimately contribute to the advancement of next-generation therapies in the field."

Simon Tremblay, PharmD, PhD, Sr. Director ofClinical Development at Veloxis Pharmaceuticals, added:
"Veloxis is committed to transforming the lives of transplant patients through innovative solutions. Collaborating with PIRCHE enables us to utilize cutting-edge molecular data to evaluate how we could refine our clinical approach. This highlights our shared dedication to pushing the boundaries of transplantation science and improving long-term graft survival."

About PIRCHE AG

PIRCHE AG provides a digital platform for molecular histocompatibility, utilizing a unique algorithm to predict indirect T-cell responses. This technology helps clinicians and researchers assess the risk of post-transplant immune responses.

For more information, visit pirche.com.

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, is a global specialty pharmaceutical company committed to improving the lives of transplant patients. Headquartered in Cary, North Carolina, USA,Veloxis is focused on the global development and commercialization of medications utilized by transplant patients and by patients with serious related diseases.

For further information, please visitVeloxis.com.

The Asahi Kasei Group contributes to life andliving for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 50,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Healthcare, Homes, and Material. Its Healthcare operations include devices and systems for acute critical care, and manufacture of biotherapeutics, as well as pharmaceuticals. For further information, please visit asahi-kasei.com.

MEDIA CONTACT

PIRCHE AG

Public Relations Department Email: pr@pirche.com

Veloxis Pharmaceuticals

Anna Michaels

Director, Corporate Communications

Veloxis Pharmaceuticals

media@veloxis.com